12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Roche sales and marketing update

Roche launched Zelboraf vemurafenib in the U.K. to treat unresectable or metastatic melanoma in patients with BRAF V600 mutations. The European Commission approved an MAA for the oral small molecule inhibitor of...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >